Navigation Links
Rib-X Pharmaceuticals Receives Award from NIAID to Develop Antibiotic Treatment for Gonorrhea
Date:9/14/2009

NEW HAVEN, Conn., Sept. 14 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of multi-antibiotic resistant infections, today announced that it intends to enter into a Clinical Trials Agreement with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services. The purpose of this agreement is to advance the clinical development of an oral formulation of Rib-X's novel fluoroquinolone delafloxacin, in the treatment of Neisseria gonorrhoeae.

N. gonorrhoeae, a gram-negative bacteria, is the cause of the sexually transmitted disease gonorrhea which affects more than 700,000 people in the United States annually. Currently, N. gonorrhoeae has become resistant to a number of antibiotics, including penicillin and other quinolones. Delafloxacin is a next-generation fluoroquinolone that has been shown to be very active against gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and a broad range of gram-negatives. In addition to work under this agreement, Rib-X is preparing to progress delafloxacin to Phase 3 clinical trials for multiple indications.

This agreement with the NIAID will further support the broad clinical potential for our lead compound, delafloxacin, which has already demonstrated potent activity against a variety of resistant bacteria and has successfully completed three Phase 2 trials," said Susan Froshauer, PhD, President and CEO of Rib-X Pharmaceuticals. "In recent years, gonococcal infections have become increasingly resistant to available antibiotic treatments and we look forward to collaborating with the team at NIAID in the coming months to evaluate possible alternative therapeutic options for such infections."

About Delafloxacin

Delafloxacin, a novel, broad spectrum, next-generation fluoroquinolone, has demonstrated better activity than other quinolones against Gram-positive bacteria, including isolates of MRSA that are quinolone-resistant. Recently, Rib-X has announced positive results from a Phase 2 trial utilizing the IV formulation of delafloxacin in complicated skin and skin structure infections (cSSSI). Delafloxacin successfully completed two previous Phase 2 trials with the oral formulation. In microbiological tests of large numbers of contemporary clinical isolates, the compound has been shown to be at least 32-fold more potent than levofloxacin, ciprofloxacin, gatifloxacin and moxifloxacin against quinolone-resistant MRSA (MIC90 of = 0.5 ug/ml for delafloxacin compared to > 16 ug/ml for all other quinolones) and twice as potent as daptomycin against MRSA. Additionally, delafloxacin was shown to more potent than ciprofloxacin against N. gonorrhoeae (MIC90 of = 0.06 ug/ml for delafloxacin compared to > 16 ug/ml for ciprofloxacin). Delafloxacin has also been shown to be more potent than existing quinolones against a range of Gram-positive, anaerobic and Gram-negative organisms. Rib-X is currently developing both IV and oral formulations of delafloxacin for use in surgical prophylaxis and other therapeutic arenas within the over $9.9 billion hospital antibiotic market.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. In addition to delafloxacin, Rib-X has completed two Phase 2 trials with radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X, as an oral/IV agent for treatment of serious Gram-positive infections. The Rx-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria and the Rx-02 discovery program is focused on developing an IV/oral macrolide active against MRSA, multidrug-resistant Streptococcus pneumoniae and S. pyogenes.

For more information on the Rib-X mission and the pipeline, please visit the Company website at www.rib-x.com.

    For further information please contact:

    Media:
    Irma Gomez-Dib
    FD Life Sciences
    Tel: 212-850-5761
    irma.gomez-dib@fd.com

    Investors:
    John Capodanno
    FD Life Sciences
    Tel: 212-850-5705
    John.capodanno@fd.com


'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
2. Rib-X Granted Key Antibiotic Patent in China
3. Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. Rib-X CEO Susan Froshauer, PhD, Honored by The Connecticut Womens Hall of Fame
5. Merz Pharmaceuticals Belotero(R) Balance PMA Filing Formally Accepted for Review by the FDA
6. Access Pharmaceuticals Signs Agreement to Manufacture Its FDA-Approved MuGard in the United States
7. Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid
8. Ritter Pharmaceuticals Hires Dr. Howard Foyt as Executive Vice President, Development & Chief Medical Officer
9. Reportlinker Adds US and European Radiopharmaceuticals Market Report
10. Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
11. Isis Pharmaceuticals to Present at Morgan Stanleys Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... Using CDRH’s Medical Device ... — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/mdqualitydata          , Device makers ... It’s known as the “CY2016 Annual FDA Medical Device Quality System Data” report. ...
(Date:7/20/2017)... ... July 20, 2017 , ... The ... Architecture Body of Knowledge (BIZBOK® Guide )v 6.0 is now available for member ... effort through Guild collaborative teams. , Non-members may download the Part 1 ...
(Date:7/20/2017)... ... July 19, 2017 , ... A local ... and increased funds raised to support fine arts programs in Chester County’s Elementary ... in Freed-Hardeman University’s Loyd Auditorium. , More than 850 people attended the ...
(Date:7/20/2017)... , ... July 19, 2017 , ... ... $1.5 million Health Resources and Services Administration (HRSA) grant to train predoctoral dental ... health care needs in rural and underserved areas. , The Predoctoral Pediatric Training ...
(Date:7/20/2017)... ... July 20, 2017 , ... “Fidget”: a fun-filled, action-packed memoir of adventures. ... school music and drama teacher who was a summa cum laude graduate of Gardner ... of the Year” award. After her retirement from public school, Lynn continued to pursue ...
Breaking Medicine News(10 mins):
(Date:6/27/2017)... BEACH, Calif. , Jun 27, 2017   NuEyes ... a round of funding to fuel its growth in helping ... ODG (Osterhout Design Group), the leading developer of ... which NuEyes technology sits. The undisclosed funding amount ... venture capital firm, Arab Angel, with offices in ...
(Date:6/20/2017)... Inc. (NYSE: HRC), will host its fiscal third quarter 2017 ... beginning at 7:30 a.m. (CDT) / 8:30 a.m. (EDT). ... the conference call, dial (877) 304-8969 (domestic) or (631) 291-4543 ... prior to the start to allow time to connect. The ... Webcast: A simultaneous webcast of the call will be ...
(Date:6/16/2017)... , June 16, 2017 Datascope Corp. is voluntarily performing ... Corp. for a potential electrical test failure code.     ... PART NUMBER ... CS300 IABP 0998-UC-0446HXX; ... This ...
Breaking Medicine Technology: